中秋夜，月亮升起，城市安静下来。直到街边的餐馆开始打烊，地铁的车也在广播里报出末班车时间。 唯有医院的灯光，没有黑过——急诊门口仍有轮椅经过，CT室的扫描声依旧低沉而坚定。 这就是中秋夜。 有人围坐赏月，有人默默值守。 Part.01 在急诊的灯光下 中秋节，是医疗体系里最特殊的节日之一。人们团圆聚餐的时刻，也正是急诊最繁忙的时候。烧伤、骨折、过敏、交通事故、突发心梗……节日的意外 从不会因为月圆而停止。 急诊医生在一线，但在他们身后，同样有人在坚守——CT和MRI的冷却系统要保持稳定，检验科的分析仪在不停运转，呼吸机、监护仪、除颤仪、注射 泵都必须随时待命。 这些设备能在关键时刻准确响应，离不开一群"隐形的医械人"——他们可能是医院的设备工程师、厂家的维保人员、或是在家中待命的技术支持。一旦 系统报警，他们会在十五分钟内赶到现场。 对他们来说，月圆的夜，不是休息的夜。 Part.02 在机器旁的人 有人在急诊科守夜，也有人在研发中心通宵。 在医疗器械的世界里，节日常常与进度表重叠。有人在测试影像算法的稳定性，有人在调试呼吸机传感器的误差补偿，有人在实验室里做最后一次验 证，只为第二天能把修复件发到医院。 有 ...

伴随资本持续注入，公司估值实现跨越式增长，从2016年初的3.2亿元升至IPO前的82.45亿元，增幅近 25倍。然而，在受到资本热捧的背后，公司实际上仍存在诸多隐忧，包括业绩真实性存疑、并购导致大 额商誉悬顶、内控合规方面问题频发等。 炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 在启动A股上市辅导近五年后，深圳麦科田生物医疗技术股份有限公司（以下简称"麦科田"）最终选择 向港交所递交上市申请，摩根士丹利与华泰国际担任其联席保荐人。回顾公司融资历史，自2016年开 始，公司一直保持着高频融资节奏，7年内累计完成10轮融资，总融资金额约22.59亿元。 这一变化与2022年的关键收购密不可分，当年麦科田将内窥镜生产商唯德康医疗收入囊中，成功切入微 创赛道。并购效应立竿见影，该业务营收从2022年的3.86亿元猛增至2024年的7.21亿元，成为绝对的增 长主力。2025年上半年继续发力，同比增长16.85%，收入达4.03亿元。 事实上，近年来并购已成为麦科田扩张业务版图的主要路径。公司在2022年1月收购英国医疗设备公司 Penlon，将生命支持业务延伸至麻醉解决方案领域；同年4 ...

Group 1 - The stock price of Zhonghong Medical is reported at 16.28 yuan, down 0.68 yuan or 4.01% from the previous trading day. The opening price was 16.60 yuan, with a high of 16.76 yuan and a low of 16.00 yuan. The trading volume was 179,500 hands, with a transaction amount of 293 million yuan [1] - Zhonghong Medical operates in the medical device industry, primarily engaged in the research, production, and sales of disposable health protective gloves and medical protective gloves. The company has made progress in overseas market expansion, completing the acquisition of 75% of SEA3 in Southeast Asia and investing in the construction of 10 nitrile glove production lines in the region [1] - The company has recently obtained several product registrations and changes, including an extension of the Class III medical device registration certificate valid until 2030, and approvals for new products such as injection pumps and enteral nutrition pumps. Its subsidiary, Jiangxi Kelun Medical Device Manufacturing Co., Ltd., has successfully renewed multiple medical device registration certificates. Additionally, the company received a patent authorization for an "anti-solvent fatigue testing device" [1] - On August 20, the net outflow of main funds was 31.4152 million yuan, accounting for 0.49% of the circulating market value. Over the past five days, the cumulative net outflow of main funds reached 86.7213 million yuan, representing 1.36% of the circulating market value [1]

Core Viewpoint - Zhonghong Medical (300981) announced that its subsidiary, Shenzhen Maide Ruina Biotechnology Co., Ltd., has recently obtained the Medical Device Registration Certificate issued by the Guangdong Provincial Drug Administration, with a registration category of Class II [1] Group 1 - The registered products include infusion pumps and infusion information collection systems, with the registration certificate valid until July 16, 2030 [1] - The models of the infusion pumps include SP90, SP90Pro, and SP90Neo, while the models of the infusion information collection systems include DS80Pro and DS90Pro [1]

中红医疗（300981）公告，子公司深圳迈德瑞纳生物科技有限公司近期取得了广东省药品监督管理局颁 发的《中华人民共和国医疗器械注册证》，迈德瑞纳申报的肠内营养泵、注射泵医疗器械注册证已审批 通过。 ...

Core Viewpoint - The stock price of Kangtai Medical has plummeted significantly since its IPO, leading to a drastic reduction in market capitalization and shareholder value, prompting the major shareholder to initiate a share reduction plan [1][2][8]. Group 1: Stock Performance and Market Capitalization - Kangtai Medical's market capitalization has dropped from over 120 billion yuan to approximately 5.46 billion yuan, representing a decline of 95.58%, which equates to a loss of about 117 billion yuan [2][7]. - The stock price reached a peak of 307.03 yuan per share at the time of listing but has since fallen to a historical low of 13.97 yuan per share [2][7]. Group 2: Financial Performance - Since 2021, Kangtai Medical has experienced a continuous decline in net profit for four consecutive years, with a reported loss of 77.9 million yuan in 2024 [3][9]. - The company's revenue has also decreased, with 2021 revenue at 909 million yuan, down 35.15% year-on-year, and subsequent years showing further declines [10][11]. - Despite the financial downturn, the company has maintained high dividend payouts, totaling approximately 392 million yuan from 2020 to 2023, with the major shareholder receiving around 230 million yuan [4][12][13]. Group 3: Shareholder Actions - On May 8, 2024, the controlling shareholder, Hu Kun, announced plans to reduce his holdings by up to 12 million shares, which could yield approximately 168 million yuan [6][7]. - This marks Hu Kun's first instance of cashing out since the company's IPO, amidst a trend of frequent share reductions by executives and shareholders since 2021 [8]. Group 4: Product Quality and Legal Issues - In 2024, Kangtai Medical faced scrutiny over product quality, with several products failing to meet standards, resulting in a fine of 30,000 yuan [16][17]. - The company was also involved in a patent infringement lawsuit with Beijing Chao Si Electronic Technology, which was settled in December 2024 for 1 million USD [19][20][21].